Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.
Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM. Vokes NI, et al. Among authors: girshman j. JCO Precis Oncol. 2019;3:PO.19.00171. doi: 10.1200/PO.19.00171. Epub 2019 Nov 12. JCO Precis Oncol. 2019. PMID: 31832578 Free PMC article.
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade.
Arbour KC, Luu AT, Luo J, Rizvi H, Plodkowski AJ, Sakhi M, Huang KB, Digumarthy SR, Ginsberg MS, Girshman J, Kris MG, Riely GJ, Yala A, Gainor JF, Barzilay R, Hellmann MD. Arbour KC, et al. Among authors: girshman j. Cancer Discov. 2021 Jan;11(1):59-67. doi: 10.1158/2159-8290.CD-20-0419. Epub 2020 Sep 21. Cancer Discov. 2021. PMID: 32958579 Free PMC article.
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Guo R, Offin M, Brannon AR, Chang J, Chow A, Delasos L, Girshman J, Wilkins O, McCarthy CG, Makhnin A, Falcon C, Scott K, Tian Y, Cecchi F, Hembrough T, Alex D, Shen R, Benayed R, Li BT, Rudin CM, Kris MG, Arcila ME, Rekhtman N, Paik P, Zehir A, Drilon A. Guo R, et al. Among authors: girshman j. Clin Cancer Res. 2021 Feb 1;27(3):799-806. doi: 10.1158/1078-0432.CCR-20-2861. Epub 2020 Nov 10. Clin Cancer Res. 2021. PMID: 33172896 Free PMC article.
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin-Romano P, Ruffinelli JC, Ponce S, Audigier-Valette C, Carnio S, Blanc-Durand F, Bironzo P, Tabbò F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz-Ares L, Dingemans AM, Planchard D, Cozic N, Cassard L, Lopes G, Chaput N, Arbour K, Besse B. Mezquita L, et al. Among authors: girshman j. Eur J Cancer. 2021 Jul;151:211-220. doi: 10.1016/j.ejca.2021.03.011. Epub 2021 May 19. Eur J Cancer. 2021. PMID: 34022698
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.
Huicochea Castellanos S, Pagano A, Plodkowski AJ, Girshman J, Hellmann MD, Rizvi H, Flynn J, Zheng J, Capanu M, Halpenny DF, Ginsberg MS. Huicochea Castellanos S, et al. Among authors: girshman j. Lung Cancer. 2021 Nov;161:60-67. doi: 10.1016/j.lungcan.2021.08.020. Epub 2021 Sep 4. Lung Cancer. 2021. PMID: 34536733 Free PMC article.
The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer.
Choudhury NJ, Lavery JA, Brown S, de Bruijn I, Jee J, Tran TN, Rizvi H, Arbour KC, Whiting K, Shen R, Hellmann M, Bedard PL, Yu C, Leighl N, LeNoue-Newton M, Micheel C, Warner JL, Ginsberg MS, Plodkowski A, Girshman J, Sawan P, Pillai S, Sweeney SM, Kehl KL, Panageas KS, Schultz N, Schrag D, Riely GJ; AACR GENIE BPC Core Team. Choudhury NJ, et al. Among authors: girshman j. Clin Cancer Res. 2023 Sep 1;29(17):3418-3428. doi: 10.1158/1078-0432.CCR-23-0580. Clin Cancer Res. 2023. PMID: 37223888 Free PMC article.
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN; CURB Study Group. Tsai CJ, et al. Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104577 Free PMC article. Clinical Trial.
30 results